This FTSE 100 stock would’ve tripled my money in 10 years. Can it happen again?

Manika Premsingh holds this FTSE 100 stock in her portfolio already, but is now wondering if it is likely to continue rising like it has in the past. 

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Plenty of high performing stocks are part of the FTSE 100 index. But not every stock is made equal. Some are definitely better buys than others and have managed to reward investors again and again. Like the the healthcare star AstraZeneca (LSE: AZN). If I had bought it 10 years ago, it would have tripled my money by now. 

AstraZeneca’s eye-watering valuation

I know that on the face of it, it comes with risks. A big one is its market valuation. I spend a fair bit of time researching cheap stocks, because they might just have the potential to rise significantly more than pricey ones. And by that argument, AstraZeneca should be an absolute no-go. Right now, it has an unbelievable price-to-earnings (P/E) ratio of 1,510 times as per my calculations based on its recently released full-year earnings report. The only other stock I have seen with such high valuations is Tesla, and there is no way I am about to buy it. 

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Scratching the surface

If I dig deeper into this story, however, it turns out that AstraZeneca’s full-year 2021 P/E has risen to crazy levels only because of a massive fall in its reported earnings, which needs to be taken with a healthy measure of salt in my view. That is because the latest drop is driven partly by the company’s acquisition of US-based rare diseases’ focused company Alexion, a move whose potential impact I had wondered about earlier as well. It is also down because of items like restructuring, amortisation, and impairments. 

If I instead consider the core earnings measure, the number that removes the noise and focuses on the earnings from the main business, it is much healthier. And it gives me a P/E of 22 times, which I think is a truer reflection of the company’s valuation. The reported number is too much of an outlier in my view to give any real perspective!

What is really going on with this FTSE 100 stock?

At this valuation, AstraZeneca does not look terrible expensive to me. I mean it is not significantly higher than that for the FTSE 100 at 16 times. And this is a healthy defensive, with a good outlook for the current year. Speaking of its outlook, the company is optimistic despite the fact that its Covid-19 related numbers are expected to weaken as the pandemic’s grip wanes. Its crucial cancer treatments are likely to hold it in good stead over the foreseeable future. And it helps that it is adding to its portfolio of products, like through the acquisition of Alexion. 

I first bought the stock a few years ago, and occasionally buy it on dips even now. It has not disappointed me so far, I look forward to buying more of it in the near future. And holding it for a long time. Because I think it could triple my money over the next decade as well. 

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Manika Premsingh owns AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Portrait of construction engineers working on building site together
Investing Articles

Is this FTSE 100 stock the best housebuilder to invest in?

One FTSE 100 housebuilding stock has outperformed all of its industry peers by a big margin this year. Should I…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

2 cheap dividend growth stocks I’d buy as the economy sinks

I'm searching for the best bargains to buy following recent market volatility. Here are two top dividend growth stocks I…

Read more »

estate agent welcoming a couple to house viewing
Investing Articles

Here’s 1 FTSE stock primed to benefit from the current housing market!

With the current housing market as it is, Jabran Khan explores a related FTSE stock that could provide stable and…

Read more »

Portrait of construction engineers working on building site together
Investing Articles

Here’s why this AIM-listed stock could be one of the best shares to buy!

This Fool is looking for the best shares to buy. Despite macroeconomic issues, this stock could be a great long-term…

Read more »

Elderly father and adult son work in the garden
Investing Articles

This penny stock could be set to soar! Should I buy shares?

This Fool looks closely at a penny stock operating in an exciting growth market that could see its shares rise…

Read more »

Illustration of bull and bear
Investing Articles

The next stock market recovery looks imminent

As the stock market bear gives way to the bull, some stocks are already turning up and I'm ready to…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

2 dividend shares to protect me from soaring inflation

Dividend shares can be an excellent way to keep up with inflation. Our writer explores several options to protect his…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is it time to buy Unilever stock?

Unilever stock has underperformed in the last five years. But with its portfolio of powerful brands, should I buy now…

Read more »